InsiderTrades

Form 4 for LTGO Latigo Biotherapeutics, Inc.

Accepted 2026-08-12 08:18:46 ET · period of report 2026-08-10 · accession 0001193125-26-345826 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2026-08-12 08:18 2026-08-10 LTGO Sanofi 10% C - Cnv Deriv — +672.8K 672.8K +6,727,780% —
DMI 2026-08-12 08:18 2026-08-10 LTGO Sanofi 10% C - Cnv Deriv — -672.8K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-08-10 C A 494,800 — 494,800 I See footnote — — (F1) The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
2 Common Common Stock 2026-08-10 C A 177,978 — 672,788 I See footnote — — (F2) The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
3 Derivative Series B Preferred Stock 2026-08-10 C D 494,800 — 0 I See footnote — · — to — 494,800 Common Stock (F1) The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. (F1) The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. (F1) The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. (F1) The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
4 Derivative Convertible Promissory Note 2026-08-10 C D 177,978 — 0 I See footnote — · — to — 177,978 Common Stock (F2) The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. (F2) The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. (F2) The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. (F2) The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. (F3) Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.